Afamelanotide

Overview

Afamelanotide is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) that activates melanocortin-1 receptors (MC1R) to stimulate eumelanin production in the skin, increasing photoprotection. It is the approved-drug form of the molecule also known as Melanotan-1, and it is FDA-approved (as Scenesse, 2019; EU-approved 2014) for prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP), a rare light-sensitivity disorder. Approval is supported by randomized controlled trials: in pooled Phase 3 data, treated EPP patients tolerated substantially more pain-free time in direct sunlight than placebo. It is delivered as a physician-administered subcutaneous implant under specialist supervision. Its approval is indication-specific — it is the melanocortin cousin of the unapproved cosmetic 'Melanotan' products, and any tanning or off-label cosmetic use is not an approved use.

Commonly Reported Uses

These are uses commonly discussed or marketed by users and vendors — not a list of proven or approved benefits, and not a recommendation.

• Prevention of phototoxicity in erythropoietic protoporphyria (FDA-approved as Scenesse)
• Increasing tolerable pain-free sunlight exposure in EPP (the approved clinical benefit)
• Skin tanning / cosmetic pigmentation — marketed for the unapproved 'Melanotan-1' research-chemical form, NOT an approved use of Scenesse

What to Track

Data points you and your clinician might monitor. For observation only — not a diagnostic protocol.

• Subjective — daily check-ins on phototoxic pain episodes and tolerable time in sunlight (the trial endpoint domain)
• Skin — pigmentation changes and full-skin monitoring for new or changing moles (melanocortin pathway); periodic dermatologic surveillance is standard with this drug
• Subjective — quality-of-life and sun-exposure behavior (key outcomes in EPP studies)
• Labs — no routine efficacy biomarker; specialist follow-up per the approved monitoring program

Sources & References

1. [1]Scenesse (afamelanotide) — European Medicines Agency EPAR overview
2. [2]Afamelanotide for Erythropoietic Protoporphyria (Langendonk et al., NEJM 2015, 373:48-59) — PubMed
3. [3]Afamelanotide — ChEMBL (approved melanocortin receptor agonist, first approval 2014)